[go: up one dir, main page]

HK1209051A1 - A method of improving liver function - Google Patents

A method of improving liver function Download PDF

Info

Publication number
HK1209051A1
HK1209051A1 HK15109811.1A HK15109811A HK1209051A1 HK 1209051 A1 HK1209051 A1 HK 1209051A1 HK 15109811 A HK15109811 A HK 15109811A HK 1209051 A1 HK1209051 A1 HK 1209051A1
Authority
HK
Hong Kong
Prior art keywords
liver function
improving liver
improving
methazolamide
therapy
Prior art date
Application number
HK15109811.1A
Other languages
English (en)
Chinese (zh)
Inventor
Ken Walder
Guy Krippner
Geoff Nicholson
Original Assignee
Verva Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verva Pharmaceuticals Ltd filed Critical Verva Pharmaceuticals Ltd
Publication of HK1209051A1 publication Critical patent/HK1209051A1/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
HK15109811.1A 2012-05-24 2013-03-15 A method of improving liver function HK1209051A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261651335P 2012-05-24 2012-05-24
US201261651335P 2012-05-24
US201261666574P 2012-06-29 2012-06-29
US201261666574P 2012-06-29
PCT/AU2013/000265 WO2013173859A1 (fr) 2012-05-24 2013-03-15 Procédé d'amélioration de la fonction hépatique

Publications (1)

Publication Number Publication Date
HK1209051A1 true HK1209051A1 (en) 2016-03-24

Family

ID=49622927

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15109811.1A HK1209051A1 (en) 2012-05-24 2013-03-15 A method of improving liver function

Country Status (15)

Country Link
US (2) US20150150855A1 (fr)
EP (1) EP2854807A4 (fr)
JP (2) JP6360826B2 (fr)
KR (1) KR20150023405A (fr)
CN (2) CN109498623A (fr)
BR (1) BR112014029308A2 (fr)
CA (1) CA2874513A1 (fr)
CO (1) CO7160082A2 (fr)
HK (1) HK1209051A1 (fr)
MX (1) MX362111B (fr)
NZ (2) NZ723206A (fr)
RU (1) RU2653478C2 (fr)
SG (2) SG10201705388XA (fr)
WO (1) WO2013173859A1 (fr)
ZA (1) ZA201408704B (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801375B (zh) 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
SG11201407786XA (en) * 2012-05-24 2015-03-30 Verva Pharmaceuticals Ltd A method of weight reduction
US10039752B2 (en) * 2016-07-21 2018-08-07 Cipla Limited Methazolamide for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2783241A (en) * 1957-02-26 S-acylimino-x-substituted-az-i
DE10035227A1 (de) * 2000-07-20 2002-01-31 Solvay Pharm Gmbh Verfahren zum Auffinden von Verbindungen, welche zur Behandlung und/oder Prophylaxe von Fettleibigkeit geeignet sind
WO2005012243A2 (fr) 2003-08-01 2005-02-10 Janssen Pharmaceutica N.V. Indole-o-glucosides substitues
CN101801375B (zh) * 2007-01-25 2014-01-01 韦尔瓦制药有限公司 胰岛素增敏剂和治疗方法
SG11201407786XA (en) * 2012-05-24 2015-03-30 Verva Pharmaceuticals Ltd A method of weight reduction

Also Published As

Publication number Publication date
JP6360826B2 (ja) 2018-07-18
JP2018090589A (ja) 2018-06-14
CA2874513A1 (fr) 2013-11-28
CO7160082A2 (es) 2015-01-15
SG11201407787VA (en) 2014-12-30
JP6412241B2 (ja) 2018-10-24
JP2015517534A (ja) 2015-06-22
CN109498623A (zh) 2019-03-22
SG10201705388XA (en) 2017-07-28
KR20150023405A (ko) 2015-03-05
US20180333399A1 (en) 2018-11-22
NZ702645A (en) 2016-08-26
EP2854807A1 (fr) 2015-04-08
CN104487073A (zh) 2015-04-01
RU2014152196A (ru) 2016-07-20
US20150150855A1 (en) 2015-06-04
BR112014029308A2 (pt) 2017-06-27
ZA201408704B (en) 2018-07-25
MX362111B (es) 2019-01-07
NZ723206A (en) 2018-02-23
MX2014014317A (es) 2015-08-10
EP2854807A4 (fr) 2016-03-16
RU2653478C2 (ru) 2018-05-08
WO2013173859A1 (fr) 2013-11-28

Similar Documents

Publication Publication Date Title
WO2012062925A3 (fr) Composés et procédés de traitement de la douleur
WO2013056148A3 (fr) Procédés d'utilisation d'antagonistes de scd1
AP2012006339A0 (en) Methods of administering pirfenidone therapy.
HK1220980A1 (zh) 用於治疗庞贝氏症的方法和组合物
HK1202549A1 (en) Donepezil pamoate, preparation method and its use
HK1197159A1 (en) Pirfenidone and anti-fibrotic therapy in selected patients
WO2013022740A3 (fr) Ligands de gpr35 et leurs utilisations
WO2014160281A3 (fr) Procédé pour améliorer l'administration de composés thérapeutiques à l'œil
WO2013098416A3 (fr) Composes anti-douleur
WO2013117744A3 (fr) Méthodes de traitement de la fibrose
SG10201703677VA (en) Methods of treating s. aureus-associated diseases
EP3137082A4 (fr) Procédés pour traiter, prévenir et améliorer des problèmes de peau
CO7160080A2 (es) Composiciones lipídicas de racecadotrillo
WO2014093999A3 (fr) Boisson alcaline
SG10201804034QA (en) Methods for treating hypotension
EP3027049A4 (fr) Traitement de boissons visant à réduire les effets de constituants nocifs
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
WO2014062878A3 (fr) Traitement du cancer avec des inhibiteurs de kinase tor
PT2770979E (pt) Composição de reticulação melhorada administrada por iontoforese, útil para o tratamento do queratocone
WO2012138223A3 (fr) Composés et procédés pour la modification de la signalisation par kinase du type du récepteur d'activine
WO2014145236A3 (fr) Utilisation de sdf-1 d'atténuation de formation de cicatrice
HK1209051A1 (en) A method of improving liver function
WO2010117727A3 (fr) Phensérine et posiphen pour le traitement d'affections neuro-psychiatriques et neurodégénératives
WO2014026013A3 (fr) Méthodes destinées à préserver ou à améliorer la santé, le bien-être et/ou une fonction physiologique chez un sujet
WO2014012025A3 (fr) Protéines igf-1 et leurs utilisations thérapeutiques